MedTrace Logo

A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia

NCT07175493 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 158

Last updated 2025-12-17

No results posted yet for this study

Summary

To evaluate the efficacy and safety of CM336 (BCMA/CD3 Bispecific Antibody) in the treatment of patients with relapsed or refractory autoimmune cytopenia

Conditions

  • Autoimmune Cytopenia
  • Immune Thrombocytopenia (ITP)
  • Autoimmune Hemolytic Anemia
  • Evans Syndrome

Interventions

BIOLOGICAL

CM336 Injection

subcutaneous CM336 administration, step-up dosing, Dose and frequency of CM336 according to the protocol

Sponsors & Collaborators

  • Keymed Biosciences Co.Ltd

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-18
Primary Completion
2027-11-18
Completion
2028-11-18

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07175493 on ClinicalTrials.gov